Advisory Committee To Decide If Azmacort, Alupent, Intal Remain "Essential" Drugs

FDA's Pulmonary–Allergy Drugs Advisory Committee will be asked at July 14 meeting whether these and other asthma products provide an otherwise unavailable important public health benefit. Drugs using chlorofluorocarbon propellants could be delisted from essential use category if closely related non-CFC alternatives exist, even though they are not the same moiety, FDA suggests.